Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.

Learn More

Stock
Quote

Volume:

04/26/2023 2:01 PMEDT

Press
Releases

05/05/2023

Pardes Biosciences Reports First Quarter 2023 Financial Results

04/03/2023

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

03/14/2023

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

02/01/2023

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

Webcasts

Financial Information

Document Date	Description	Form	View
12/23/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-067222.pdf 0001213900-21-067222.rtf 0001213900-21-067222.xls
02/18/2021	Form of prospectus disclosing information facts events covered in both forms 424B1 424B3	424B4	View HTML 0001213900-21-010337.pdf 0001213900-21-010337.rtf 0001213900-21-010337.xls
12/01/2021	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0001213900-21-062759.pdf 0001213900-21-062759.rtf 0001213900-21-062759.xls
02/01/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0001193125-22-024690.pdf 0001193125-22-024690.rtf 0001193125-22-024690.xls
02/15/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0001193125-22-042532.pdf 0001193125-22-042532.rtf
03/02/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0000950170-22-002678.pdf 0000950170-22-002678.rtf 0000950170-22-002678.xls
04/01/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0001193125-22-093583.pdf 0001193125-22-093583.rtf 0001193125-22-093583.xls
05/10/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0000950170-22-009019.pdf 0000950170-22-009019.rtf 0000950170-22-009019.xls
06/09/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0000950170-22-011353.pdf 0000950170-22-011353.rtf 0000950170-22-011353.xls
06/10/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0000950170-22-011481.pdf 0000950170-22-011481.rtf 0000950170-22-011481.xls

Contact
IR

Send us an investor-related question using the form below.